Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Polynovo ( (AU:PNV) ) has provided an update.
At the Annual General Meeting held on October 28, 2025, PolyNovo Limited successfully passed several key resolutions, including the re-election of directors Leon Hoare and David Williams, and the election of Robert Douglas as a director. The adoption of the remuneration report and approval of non-executive directors’ fees were also carried. These outcomes reflect strong shareholder support and are expected to positively impact the company’s governance and strategic direction.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo Limited operates in the medical technology industry, focusing on the development and commercialization of innovative medical devices. The company is primarily known for its NovoSorb technology, which is used in wound care and surgical applications, targeting both domestic and international markets.
Average Trading Volume: 3,567,687
Technical Sentiment Signal: Sell
Current Market Cap: A$894.6M
For a thorough assessment of PNV stock, go to TipRanks’ Stock Analysis page.